ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors.

Lillian L Siu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.